Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis
Ashwin Kishtagari, MD, discusses the treatment of patients with myelofibrosis following progression on ruxolitinib.
Vanderbilt University United States Ashwin Kishtagari Department Of Hematology Vanderbilt University Medical Center Vanderbilt Stem Cell Transplant
Source: onclive.com